dinaline has been researched along with Adenocarcinoma, Basal Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corbett, TH; Foster, BJ; Jones, L; LoRusso, PM; Wiegand, R | 1 |
| Berger, MR; Eibl, H; Richter, H; Schmähl, D; Seelig, MH | 1 |
2 other study(ies) available for dinaline and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Area Under Curve; Benzamides; Blood Cell Count; Bone Marrow; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Metabolic Clearance Rate; Mice; Phenylenediamines | 1997 |
New cytostatics--more activity and less toxicity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; Male; Mammary Neoplasms, Experimental; Ovariectomy; Phenylenediamines; Phosphorylcholine; Rats; Rats, Inbred Strains; Remission Induction; Structure-Activity Relationship | 1990 |